0000000001134645

AUTHOR

Marcello Maugeri-saccà

showing 7 related works from this author

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

2017

ObjectiveCancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies.DesignTo discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein mic…

0301 basic medicinep53DNA ReplicationCELL CYCLE CONTROLDNA damageColorectal cancerColonmedicine.medical_treatmentAntineoplastic AgentsBiologyBioinformaticsmedicine.disease_causeDNA DAMAGETargeted therapy03 medical and health sciencesCancer stem cellCell Line TumormedicineHumansCHEK11506DRUG DEVELOPMENTOligonucleotide Array Sequence AnalysisMutationCOLORECTAL CANCERSettore MED/06 - ONCOLOGIA MEDICAGastroenterologyCHEMOTHERAPYmedicine.diseaseImmunohistochemistryPrexasertib030104 developmental biologyPyrazinesCheckpoint Kinase 1MutationCancer researchNeoplastic Stem CellsPyrazolesStem cellTumor Suppressor Protein p53Colorectal NeoplasmsGut
researchProduct

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the r…

2021

Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-l…

Oncologymedicine.medical_specialtyAdvanced breastT-DM1Treatment outcomeLapatinibBreast cancerpertuzumabInternal medicineMedicinelapatinibRC254-282advanced breast cancerbusiness.industryHuman epidermal growth factoradvanced breast cancer; HER2-positive; lapatinib; pertuzumab; sequence; T-DM1Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancersequencemedicine.diseaseHER2-positiveOncologyObservational studyPertuzumabbusinessmedicine.drug
researchProduct

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

2021

Breast cancer (BC) heterogeneity is composite in nature, with a wide variety of factors concurring to define several pathological entities, which differ by clinical presentation, pathologic features, therapy administered, and inherent outcomes1. Additional sources of breast cancer heterogeneity may raise during the disease course. In BC patients whose disease was initially diagnosed in the early stage and subsequently progressed with metastatic involvement of one single or multiple site/s, the molecular characteristics of metastatic lesions do not necessary mimic those of the disease initially diagnosed. A well-depicted molecular landscape is crucial for subtype definition, prognostic evalu…

0301 basic medicineOncologyCancer therapyReceptor ErbB-2medicine.medical_treatmentAdo-Trastuzumab Emtansineprogesterone receptorSettore MED/060302 clinical medicinehuman epidermal growth factor receptor 2 (HER2)Antineoplastic Combined Chemotherapy ProtocolsestrogenNeoplasm Metastasisskin and connective tissue diseasesMultidisciplinaryBrain NeoplasmsQRMiddle AgedPrognosisMetastatic breast cancerNeoplasm Metastasi030220 oncology & carcinogenesisMedicineFemalePertuzumabmetastatic breast cancerReceptors ProgesteroneBreast NeoplasmHER2 positivitymedicine.drugHumanAdultmedicine.medical_specialtymedicine.drug_classSciencetrastuzumab-emtansineBreast Neoplasmsmetastatic breast cancer; HER2 positivity; cancerArticleDisease-Free SurvivalBrain Neoplasm03 medical and health sciencesBreast cancerbreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicineProgesterone receptormedicineHumanscancerbreast cancer; human epidermal growth factor receptor 2 (HER2); pertuzumab; trastuzumab-emtansine; estrogen; progesterone receptorneoplasmsAgedChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancermedicine.diseaseHER2-positiveBreast cancer; oncology; radiotherapy; chemotherapy; HER2Radiation therapy030104 developmental biologyEstrogenbusinessprognostic relevance
researchProduct

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

2015

Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs…

cancer stem cellsTAZAnimals; Biomarkers Tumor; Breast Neoplasms; Cell Line Tumor; Disease-Free Survival; Female; Gene Expression Regulation Neoplastic; Humans; Mice; Neoplasm Metastasis; Neoplasm Recurrence Local; Neoplastic Stem Cells; Transcription Factors; Xenograft Model Antitumor AssaysCancer ResearchBioinformaticschemotherapyMetastasistaz; breast cancerMiceNeoplasm Metastasiseducation.field_of_studyTumorIntracellular Signaling Peptides and ProteinsCell cycleGene Expression Regulation NeoplasticLocalNeoplastic Stem Cellsbreast cancer; cancer stem cells; chemotherapy; metastasis; TAZ; Animals; Biomarkers Tumor; Breast Neoplasms; Cell Line Tumor; Disease-Free Survival; Female; Gene Expression Regulation Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; Neoplasm Metastasis; Neoplasm Recurrence Local; Neoplastic Stem Cells; Xenograft Model Antitumor Assays; Molecular Biology; Genetics; Cancer ResearchFemaleStem cellPopulationBreast NeoplasmsBiologyDisease-Free SurvivalCell Linebreast cancer cancer stem cells TAZBreast cancerbreast cancerCancer stem cellSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicineBiomarkers TumorGeneticsmetastasisAnimalsHumanseducationMolecular BiologyHippo signaling pathwayNeoplasticCancermedicine.diseaseXenograft Model Antitumor AssaysNeoplasm RecurrenceGene Expression RegulationTranscriptional Coactivator with PDZ-Binding Motif ProteinsCancer researchTrans-ActivatorsNeoplasm Recurrence LocalBiomarkersTranscription Factors
researchProduct

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct

Additional file 1 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER St…

2020

Additional file 1.

Data_FILES
researchProduct

Additional file 2 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER St…

2020

Additional file 2.

Data_FILES
researchProduct